Therapeutic potential of paeoniflorin in atherosclerosis: A cellular action and mechanism-based perspective

Front Immunol. 2022 Dec 21:13:1072007. doi: 10.3389/fimmu.2022.1072007. eCollection 2022.

Abstract

Epidemiological studies have shown that the incidence, prevalence and mortality of atherosclerotic cardiovascular disease (ASCVD) are increasing globally. Atherosclerosis is characterized as a chronic inflammatory disease which involves inflammation and immune dysfunction. P. lactiflora Pall. is a plant origin traditional medicine that has been widely used for the treatment of various diseases for more than a millennium in China, Japan and Korean. Paeoniflorin is a bioactive monomer extracted from P. lactiflora Pall. with anti-atherosclerosis effects. In this article, we comprehensively reviewed the potential therapeutic effects and molecular mechanism whereby paeoniflorin protects against atherosclerosis from the unique angle of inflammation and immune-related pathway dysfunction in vascular endothelial cells, smooth muscle cells, monocytes, macrophages, platelets and mast cells. Paeoniflorin, with multiple protective effects in atherosclerosis, has the potential to be used as a promising therapeutic agent for the treatment of atherosclerosis and its complications. We conclude with a detailed discussion of the challenges and future perspective of paeoniflorin in translational cardiovascular medicine.

Keywords: atherosclerosis; cardiovascular disease; immunity; inflammation; paeoniflorin.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endothelial Cells*
  • Glucosides* / pharmacology
  • Glucosides* / therapeutic use
  • Humans
  • Inflammation / drug therapy
  • Monoterpenes / pharmacology
  • Monoterpenes / therapeutic use

Substances

  • peoniflorin
  • Glucosides
  • Monoterpenes